Clinical trial
A Phase 1, Open-Label, Multi-Center Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Intravenous and Oral Doses of Omadacycline in Pediatric Subjects With Suspected or Confirmed Bacterial Infections
NCT05217537 is registered in ClinicalTrials.gov with Paratek Pharmaceuticals Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open-Label, Multi-Center Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Intravenous and Oral Doses of Omadacycline in Pediatric Subjects With Suspected or Confirmed Bacterial Infections
- Lead sponsor
- Paratek Pharmaceuticals Inc
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- April 6, 2022
- Completion date
- February 27, 2025
- Enrollment
- 23 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.